SCHEMBL2779337

SCHEMBL2779337

O=C(O)c1cccc2cccc(-c3c4ccc(=O)c(O)c-4oc4c(O)c(O)ccc34)c12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GNG2 P59768 9/20 1.00
GNB1 P62873 9/20 1.00
KDM4A O75164 1/20 0.57
USP2 O75604 1/20 0.57
NSD2 O96028 1/20 0.57
ALPL P05186 1/20 0.57
PLCG1 P19174 1/20 0.57
TNNI3 P19429 1/20 0.57
NFKB1 P19838 1/20 0.57
TNNT2 P45379 1/20 0.57
MMP14 P50281 1/20 0.57
CASP6 P55212 1/20 0.57
TNNC1 P63316 1/20 0.57
KDM4C Q9H3R0 1/20 0.57
L3MBTL1 Q9Y468 1/20 0.57
PTPN7 P35236 1/20 0.49
HSD17B10 Q99714 6/20 0.49
HPGD P15428 5/20 0.49
ALOX15 P16050 5/20 0.49
HSPA1A P0DMV8 4/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2777300 0.88 GNG2 (1.00) GNG2GNB1KDM4AUSP2NSD2
SCHEMBL2782525 0.82 GNG2 (0.70) GNG2GNB1KDM4AUSP2NSD2
SCHEMBL13320794 0.82 GNG2 (0.69) GNG2GNB1KDM4AUSP2NSD2
SCHEMBL2848097 0.80 GNG2 (0.80) GNG2GNB1KDM4AUSP2NSD2
SCHEMBL2777698 0.79 GNG2 (0.69) GNG2GNB1KDM4AUSP2NSD2
SCHEMBL13352283 0.76 GNG2 (0.71) GNG2GNB1KDM4AUSP2NSD2
SCHEMBL7820781 0.76 GNG2 (0.59) GNG2GNB1KDM4AUSP2NSD2
SCHEMBL2840949 0.76 GNG2 (0.64) GNG2GNB1KDM4AUSP2NSD2
SCHEMBL2848109 0.75 GNG2 (0.65) GNG2GNB1KDM4AUSP2NSD2
SCHEMBL13891771 0.74 GNG2 (0.61) GNG2GNB1KDM4AUSP2NSD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100130505-A1 COMPOSITIONS AND METHODS FOR INHIBITING G PROTEIN SIGNALING UNIVERSITY OF ROCHESTER (US) 2010-05-27 US claimed
EP-2147310-A2 COMPOSITIONS AND METHODS FOR INHIBITING G PROTEIN SIGNALING University of Rochester (US) 2010-01-27 EP claimed
EP-1210108-B1 USE OF LEPTIN TOGETHER WITH AN INHIBITOR OF VEGF AND/OR AN INHIBITOR OF ANGIOGENESIS FOR THE INHIBITION OF ENDOTHELIAL CELL PROLIFERATION YEDA RES & DEV (IL) 2009-11-25 EP claimed
WO-2009020677-A9 COMPOSITIONS AND METHODS FOR INHIBITING G PROTEIN SIGNALING UNIV ROCHESTER (US) 2009-04-16 WO claimed
WO-2009020677-A2 COMPOSITIONS AND METHODS FOR INHIBITING G PROTEIN SIGNALING UNIVERSITY OF ROCHESTER (US) 2009-02-12 WO claimed
EP-1210108-A2 USE OF LEPTIN IN INHIBITION OF ENDOTHELIAL CELL PROLIFERATION Yeda Research and Development Co. Ltd. (IL) 2002-06-05 EP claimed
WO-2001018040-A2 USE OF LEPTIN IN INHIBITION OF ENDOTHELIAL CELL PROLIFERATION YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) 2001-03-15 WO claimed
US-8975259-B2 Compositions and methods for inhibiting G protein signaling UNIVERSITY OF ROCHESTER (US) 2015-03-10 US disclosed
US-8975259-B2 Compositions and methods for inhibiting G protein signaling UNIVERSITY OF ROCHESTER (US) 2015-03-10 US disclosed
US-8975259-B2 Compositions and methods for inhibiting G protein signaling UNIVERSITY OF ROCHESTER (US) 2015-03-10 US disclosed
US-8748480-B2 Methods for treating opioid tolerance UNIVERSITY OF ROCHESTER (US) 2014-06-10 US disclosed
US-8748480-B2 Methods for treating opioid tolerance UNIVERSITY OF ROCHESTER (US) 2014-06-10 US disclosed
US-20130116313-A1 Compositions and Methods for Inhibiting G Protein Signaling UNIVERSITY OF ROCHESTER (US) 2013-05-09 US disclosed
US-20060094657-A1 Inhibiting development of microvessels within coronary or peripheral vessel walls for restenosis/atherosclerosis prevention or therapy CARDIOVASCULAR RESEARCH FOUNDATION 2006-05-04 US disclosed
US-20030191055-A1 Inhibiting development of microvessels withins coronary or peripheral vessel walls for restenosis/atherosclerosis prevention or therapy CARDIOVASCULAR RESEARCH FOUNDATION 2003-10-09 US disclosed
EP-1146891-A4 INHIBITING DEVELOPMENT OF MICROVESSELS WITHIN VASCULAR WALLS MEDSTAR RES INST (US) 2002-07-17 EP disclosed
EP-1210108-A2 USE OF LEPTIN IN INHIBITION OF ENDOTHELIAL CELL PROLIFERATION Yeda Research and Development Co. Ltd. (IL) 2002-06-05 EP disclosed
EP-1146891-A1 INHIBITING DEVELOPMENT OF MICROVESSELS WITHIN VASCULAR WALLS Medstar Research Institute (US) 2001-10-24 EP disclosed
WO-2001018040-A2 USE OF LEPTIN IN INHIBITION OF ENDOTHELIAL CELL PROLIFERATION YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) 2001-03-15 WO disclosed
WO-2000041712-A1 INHIBITING DEVELOPMENT OF MICROVESSELS WITHIN VASCULAR WALLS CARDIOVASCULAR RESEARCH FOUNDATION (US) 2000-07-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116313-A1 Compositions and Methods for Inhibiting G Protein Signaling GNAI3, GNAI1, GNAI2 GNG2 7/4885GNB1 4/4885KDM4A 4720/4885
US-20100130505-A1 COMPOSITIONS AND METHODS FOR INHIBITING G PROTEIN SIGNALING GNAI1, GNAI3, GNAI2 GNG2 5/4885GNB1 4/4885KDM4A 4751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.